{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:31:46Z","timestamp":1790220706241,"version":"4.1.0"},"reference-count":7,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec id=\"ab-des260001-1\">\n                    <jats:title>Clinical Question<\/jats:title>\n                    <jats:p>Among adults with moderate to severe plaque psoriasis, how do systemic treatments compare in attaining a Psoriasis Area and Severity Index 90 (PASI 90) response and the occurrence of serious adverse events?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-des260001-2\">\n                    <jats:title>Bottom Line<\/jats:title>\n                    <jats:p>Biologic therapies, particularly interleukin (IL)\u201317 and IL-23 inhibitors, provide the highest short-term likelihood of achieving PASI 90, while existing oral agents offer more modest efficacy but remain important options for patients who prefer noninjectable treatments. Severe adverse events were uncommon across all therapies and similar to placebo in the short term.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.0200","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:30:52Z","timestamp":1774452652000},"page":"525","source":"Crossref","is-referenced-by-count":4,"title":["Systemic Pharmacological Treatments for Chronic Plaque Psoriasis"],"prefix":"10.1001","volume":"162","author":[{"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[{"name":"Division of Dermatology, University of California Los Angeles, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Nong","sequence":"additional","affiliation":[{"name":"Division of Dermatology, University of California Los Angeles, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O\u2019Donnell School of Public Health, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"des260001r1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis.","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"des260001r2","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis.","volume":"8","author":"Sbidian","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"des260001r3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis.","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"3","key":"des260001r4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","article-title":"Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis.","volume":"85","author":"Shear","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"des260001r5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2025.1625","article-title":"Defining on-treatment remission in plaque psoriasis: a consensus statement from the National Psoriasis Foundation.","volume":"161","author":"Armstrong","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"10201","key":"des260001r6","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"10510","key":"des260001r7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(25)01576-4","article-title":"Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.","volume":"406","author":"Gold","year":"2025","journal-title":"Lancet"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2846492\/jamadermatology_armstrong_2026_es_260001_1779281423.50736.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:00:27Z","timestamp":1779289227000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2846492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.0200","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}